LETHAL INJECTION: British Manufacturer Stops Drug Supply to Arkansas for Executions
The British manufacturer Hikma Pharmaceuticals recently announced new rules to restrict the supply of its products for unintended uses, such as carrying out executions in the United States. Earlier this year, Reprieve, a legal advocacy organization based in London, found that a U.S. subsidiary of Hikma sold 100 grams of phenobarbital to the Arkansas Department of Corrections. Arkansas decided to use the new, untested drug in their lethal injection process when they were unable to secure supplies of the drugs they normally use. A spokesman for Hikma Pharmaceuticals said the order had been made as part of the regular request for drugs for prison hospital services and did not raise any red flags because the drug had never been used in executions before. Arkansas has been contacted by the drug company and told that the subsidiary was closing the account. The state's current supply of phenobarbital is sufficient to carry out eight executions and will expire in October 2015. The state will need to seek alternative sources or different drugs when their current supply becomes unavailable. Other drug companies have put similar restrictions on the use of their drugs in executions.
There are no execution dates set in Arkansas, and legal challenges to the execution protocol continue.
(E. Pilkington, "British maker of death penalty drugs adds new restrictions for US buyers," The Guardian, May 15, 2013). See Executions and Lethal Injection.